Early onset of ganciclovir-resistant cytomegalovirus infection in a lung-transplant recipient.
Ganciclovir resistance in cytomegalovirus (CMV) is an increasing problem in lung-transplant recipients with adverse clinical outcomes. We experienced the successful treatment of ganciclovir-resistant CMV infection in a lung-transplant recipient still receiving CMV prophylaxis. A 24-year-old woman with lymphangioleiomyomatosis underwent a living-donor lobar lung transplantation. She was a primary CMV mismatch (D+/R-) patient. She recovered from her postoperative complications, and was about to be discharged. However, she suffered ganciclovir-resistant CMV infection during prophylactic therapy. She was successfully treated with foscarnet, and is now alive without recurrence 18 months after surgery.
Chen
Fengshi
F
Department of Thoracic Surgery, Kyoto University, Japan.
Bando
Toru
T
Hanaoka
Nobuharu
N
Fukuse
Tatsuo
T
Hasegawa
Seiki
S
Wada
Hiromi
H
D000328:Adult; D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000209:etiology*; D024882:Drug Resistance, Viral; D005260:Female; D017245:Foscarnet / Q000627:therapeutic use; D015774:Ganciclovir / Q000494:pharmacology*; D006801:Humans; D016040:Lung Transplantation; D011183:Postoperative Complications
D000998:Antiviral Agents; D017245:Foscarnet; D015774:Ganciclovir